Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027

Moleculin completes dosing in key AML trial but faces long wait for critical data.

What the company is saying

Moleculin Biotech, Inc. reports the completion of dosing in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin plus cytarabine (AnnAraC) for adults with relapsed or refractory acute myeloid leukemia. The company frames this as a major operational milestone, emphasizing that comprehensive Part A data for the full 90-patient cohort will be available in Q1 2027. The narrative highlights a balanced patient mix—projected to be a 50/50 split between those who failed 7+3 chemotherapy and venetoclax-based regimens—contrasting with the earlier 70/30 split among the first 45 subjects. Management, led by Chairman and CEO Walter Klemp, stresses the absence of cardiotoxicity in blinded interim data and positions the upcoming data as pivotal for dose selection in Part B and for defining Annamycin’s role in R/R AML. The company also contextualizes its trial design as more stringent than historical benchmarks, since remission rates will be measured after only a single therapy cycle. The announcement acknowledges that further progress is contingent on securing significant additional financing, for which there are currently no commitments.

What the data suggests

The only realised milestone is completion of dosing for Part A in the MIRACLE trial, with the final dataset expected to include 90 patients and a targeted 50/50 split between key patient subgroups. All trial arms, including the control, received just one cycle of therapy, which is less than in comparator studies, setting expectations for lower absolute remission rates. The only safety data disclosed is the continued absence of cardiotoxicity in blinded interim results; no efficacy or detailed safety outcomes are provided. The company confirms that the comprehensive Part A analysis will inform dose selection for Part B, but no interim efficacy data or statistical details are given. The announcement is operationally transparent regarding trial design and timelines but lacks quantitative clinical or financial results. The company explicitly states it will require significant additional financing to continue, with no funding secured at this stage.

Analysis

The announcement's tone is upbeat, emphasizing the completion of dosing in Part A of the pivotal Phase 2/3 MIRACLE trial and projecting confidence about the future potential of Annamycin. However, the only realised milestone is the operational completion of dosing; no efficacy or comprehensive safety data are disclosed, aside from the continued absence of cardiotoxicity in interim data. Most key claims are forward-looking, including expectations for the Q1 2027 data readout, the potential for dose selection, and the assertion that the development pathway is 'substantially de-risked.' The anticipated benefits (potential approval, efficacy, and commercial impact) are long-term, with the next major data catalyst not expected until Q1 2027—over a year away. The company explicitly states it will require significant additional financing, with no commitments in place, highlighting a high capital intensity paired with uncertain, long-dated returns. The narrative inflates progress by suggesting de-risking and future potential without supporting data, while the actual evidence is limited to trial process milestones.

Risk flags

• ●There is a substantial financing risk: Moleculin states it requires significant additional funding to conduct its clinical trials as planned, and currently has no commitments in place. This introduces the possibility of trial delays, program discontinuation, or dilutionary financings if capital cannot be raised.
• ●Execution risk is elevated due to the long timeline to the next catalyst, with comprehensive Part A data not expected until Q1 2027. This leaves the company exposed to operational setbacks, patient attrition, or regulatory changes over an extended period.
• ●Clinical risk remains high, as no efficacy or detailed safety data have been disclosed. The only safety signal is the absence of cardiotoxicity in interim data, but the ultimate therapeutic benefit of Annamycin plus cytarabine remains unproven until the Q1 2027 readout.
• ●Comparability risk is present because the trial’s single-cycle design differs from historical benchmarks, which allowed multiple cycles. This may complicate interpretation of remission rates and could limit the perceived strength of positive results.

Bottom line

Moleculin has reached a procedural milestone by completing dosing in Part A of its pivotal AML trial, but investors face a long wait for any efficacy or comprehensive safety data, with the next readout not due until Q1 2027. The company is transparent about its need for significant new funding, and the absence of committed capital raises the risk of delays or dilution. The trial’s design—measuring remission after only one cycle—may make results harder to compare to historical studies, increasing uncertainty about regulatory and market impact. No efficacy data or interim results are provided, so the current narrative is built on operational progress rather than clinical evidence. The most important takeaway is that while the trial is advancing procedurally, the investment case hinges on both the Q1 2027 data and the company’s ability to secure financing in the interim.

Announcement summary

(NASDAQ:MBRX) Moleculin Biotech, Inc. announced the completion of dosing in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for adults with relapsed or refractory acute myeloid leukemia (R/R AML). The company remains on track to report comprehensive Part A data in the first quarter of 2027. The MIRACLE trial is a randomized, double-blind, placebo-controlled Phase 2/3 study comparing two different doses of Annamycin plus cytarabine to a control arm of cytarabine plus placebo, with all arms receiving just one cycle of therapy. The final Part A population is expected to include approximately 90 patients, with an anticipated 50/50 split between those who failed intensive 7+3 chemotherapy and those who failed venetoclax-based regimens, compared to a 70/30 split among the first 45 subjects. The comprehensive Part A analysis will evaluate efficacy and safety across the complete randomized population and support selection of the optimal Annamycin dose for advancement into Part B of the trial. Remission rates for all three arms, including the control arm, will reflect outcomes measured after only a single cycle of therapy, which differs from historical benchmarks such as the MIRROS and CLASSIC I studies and Moleculin’s own MB-106 study that permitted multiple cycles. The company notes the continued absence of cardiotoxicity in blinded interim data. The MIRACLE trial is registered under ClinicalTrials.gov Identifier NCT06788756. Moleculin’s lead program, Annamycin (also known as naxtarubicin), is designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is also in development for soft tissue sarcoma (STS) lung metastases. The company is also developing WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic, and other cancers, and WP1122 for the potential treatment of pathogenic viruses and certain cancer indications. Walter Klemp, Chairman and Chief Executive Officer of Moleculin, stated that completion of dosing in Part A is an important step toward the planned Q1 2027 comprehensive n=90 data readout and that the data will help define Annamycin's potential role in R/R AML. The company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin for AML, following a successful Phase 1B/2 study (MB-106) and input from the FDA. The study remains subject to appropriate future filings and potential additional feedback from the FDA and their foreign equivalents.

Disagree with this article?